PTN logo

PALATIN TECHNOLOGIES INC

PTNNASDAQ
🏆 #4861 by market capEarnings Nov 11US Equity
$5.08▲ $0.28 (+5.94%)
Market closed · at close
🔔
Track PTN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.9%
7d▼ 10.7%
14d▼ 25.2%
30d▼ 45.8%
ytd▼ 66.1%
1y—
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
99.6%
High
💵FCF Margin
-103.0%
Thin
⚖️P/S Ratio
0.7x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$5.01 – $5.17
52-Week Range
$4.51 – $31.00
Volume (shares)
1,143
Avg Volume (shares)
—
Shares Outstanding
1.8M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$13M
Last Q Revenue
$300,770
P/E Ratio
-1.0
P/S Ratio
0.7x
EPS (TTM)
$-2.14
Dividend Yield
0.00%
Dilution (1yr)
+257.0%
PTN logo

PALATIN TECHNOLOGIES INC

PTN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$13M▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.5%▲ +1.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −50.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14M▼ −36.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.9M▲ +257.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▼ −$7M YoY
StockOtter · stockotter.space

About PALATIN TECHNOLOGIES INC

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.